Loading...
Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials
Apalutamide (ARN-509) is a second-generation androgen receptor (AR) antagonist that was developed to inhibit AR-mediated prostate cancer cell proliferation. Following the initial promising clinical efficacy results in phase I and II clinical trials of patients with metastatic castrate-resistant pros...
Saved in:
| Published in: | Ther Adv Urol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
SAGE Publications
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6295778/ https://ncbi.nlm.nih.gov/pubmed/30574205 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287218811450 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|